Radioembolization Therapy Market Manufacturers Profiles, Market Size and Market Share 2022

According to the latest research by Persistence Market Research, the Radioembolization Therapy market is set to witness a 6.7% growth during the year 2021-2031.

The market is expected to witness growth owing to the increasing prevalence of liver cancer and hepatocellular cancer together with more focus of the key players on technological advancements. Also, increasing spending on the development of healthcare infrastructure particularly in developing nations is contributing to the development of the market.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32991

Some of the leading manufacturers and suppliers of Radioembolization Therapy include:

• Terumo Corporation
• Merit Medical Systems Inc.
• Cook Medical
• Boston Scientific Corporation
• Medtronic plc
• Stryker Corporation
• Depuy Synthes (J&J)
• BTG International Limited

The Radioembolization Therapy market is competitive. Also, key manufacturers are focusing on market expansion strategies in order to increase their foothold in the market. Additionally, major companies are spending extensively in the research and development activities to develop innovative products.

Worldwide, they are involved in long term collaborations with pharmaceutical companies, and are involved into alliances with other players in various countries to expand their business.

The demand for the global market for radioembolization therapy is anticipated to grow on account of the increasing incidence of several types of hepatic cancer and the rising demand for minimally invasive procedure.

Moreover, the increasing expenditure to improve healthcare infrastructure and the growing research and development activities for technological advancements in the healthcare sector is expected to drive growth of radioembolization therapy market.

The rising prevalence of various chronic diseases, such as cancer, are anticipated to boost the global radioembolization therapy market over the forecast period. As per the CDC (Centre for Disease Control and Prevention) report, in the US, 33,000 people are detected with liver cancer every year.

Among these, more than 27,000 people die from the disease and among which 10,000 women and 24,000 men get liver cancer, and around 9,000 women and 18,000 men die from the illness.

Moreover, the rate of people suffering from liver cancer has gradually been rising in the last decade. In addition, the rate of survival more than five years is tremendously low, with the percentage remaining between 4% -26%.

The US and Canada radioembolization therapy market is anticipated to witness a healthy growth in the market due to growing number of ASCs (ambulatory surgery center) and increasing geriatric population in the US and Canada.

Also, developing preference for minimally invasive procedures have given rise to increased adoption of radioembolization procedures in these nations. As per the U.S. department of health and human services, Ambulatory surgery has shown to be popular amongst both patients and physicians and the amount of Medicare certified ambulatory surgery centers has risen steadily. These factors are contributing to the growth of market in US and Canada.

Europe is anticipated to be second leading region for market due to various factors. European market is set to witness gradual growth mainly because of the growing prevalence & incidence of cancer; availability of treatment and increasing awareness regarding overall health.

Moreover, initiatives such as funding and grants taken by government for the development of advanced techniques by means of interventional oncology will drive the market growth.

Pre-Book Right Now for Exclusive Analyst Support@ https://www.persistencemarketresearch.com/checkout/32991

Transparency Market Research is here to provide companies a one-stop solution with regards to bettering customer experience.